TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05491525: Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

Sponsor: Urovant Sciences GmbH · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 71 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,118,808

Rescue Site Savings

+$2,065,704

Unlock Full NCT05491525 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05491525 Rescue Dossier →